Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.
about
High-grade glioma management and response assessment-recent advances and current challengesQuantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR ImagesModern brain tumor imagingRecent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma PatientsEmerging Techniques in Brain Tumor Imaging: What Radiologists Need to KnowPerfusion MRI: the five most frequently asked clinical questions.Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.Pseudoprogression in high-grade glioma.Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunitiesMeasurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumoursRelative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastomaThe Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.MR-guided radiation therapy: transformative technology and its role in the central nervous system.Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidenceHigh levels of cellular proliferation predict pseudoprogression in glioblastoma patientsTrue progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysisImaging genomics in cancer research: limitations and promisesStratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome.Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: A pilot study.Pseudoprogression after glioma therapy: a comprehensive review.Current status of antiangiogenic therapies for glioblastomas.Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging.Amino acid PET and MR perfusion imaging in brain tumours.Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysisMRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics studyNoninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.
P2860
Q26740664-586C9DA5-CD48-48B1-B2A7-54AAFA9C4082Q26743358-7DF08872-6383-496D-AAEE-5EC44374DBD4Q27002344-A6752DA1-1C64-4DB0-B831-9043187FB0CFQ28066044-B934EECE-6DFA-433B-B8A3-90E8998BA414Q28068259-918CC04C-33F7-4252-8F7F-2084C5DAFC18Q30416198-D5A5C36A-E476-4C7B-AE68-64979E2A71BDQ30571373-01D023A3-2137-4ACC-8C91-7BE86872B2B7Q30578798-330F81F2-0E27-42B1-87DE-969F55CE2204Q30627773-8BDF6F05-007C-455A-BEEB-3CA004A7B9E3Q30653828-59DF36CC-5C0A-45FA-B397-88A043237325Q30818733-1FC9B61E-0E69-49BF-98C9-98349A242720Q30938805-3FBA6A88-447E-4310-92BB-D871172C1C81Q33616589-933F1766-1FC5-4D6F-8900-7F086DDC7728Q33894461-91C8F7A2-9659-4052-9E0C-B516F90D1357Q34560322-CD096539-BB82-44E9-AFD0-80031FC2AB8FQ35771783-8AFBD6CE-EF71-4894-AACA-DBF150573790Q35811181-86EF7BDC-1DEE-420B-9075-314485B6D4CDQ35815295-086F5883-3651-4383-AE95-F5F4D2008F50Q36095642-9E15D5D1-BE85-485C-9726-6AD1724B174CQ36097886-AD2B692D-E8FE-49B1-AE09-34BDD40606D8Q36265476-97F64499-D395-481F-B251-E2ACAEE6DEBFQ36336361-489F122D-850F-462C-A5FC-23E586D999E5Q36361484-A43B4FA8-5806-4855-BB49-35D4E4DF8090Q36459981-9663CC4B-F654-4D49-BDC7-44DDDDC7B0CFQ36515232-2861D5FB-00F6-4FC4-B97B-826D685EA257Q36645695-4B4FC7C6-8C58-449E-9525-9AFF7E4EE4C9Q37050436-E16E97D4-A330-415C-BFC7-016F9FF39F85Q37176568-C91B09F8-F7F0-4BF0-BE98-67F13E6201DDQ37321862-5F65A8A4-F320-4BA4-AFED-CD3A611D88CBQ37492118-BCB2680F-A9FD-4367-BB4B-DE8A9D7E07E9Q37523107-3375A737-0D5C-485D-AE16-1465F1D124B2Q37963395-AFCD81E6-234D-4BA1-849E-CA3020950728Q38094809-F7377E34-82F1-42D2-BEB1-E5C480ED7406Q38169761-E5793AE6-BDB9-4DDE-83FB-548364F7CA79Q38471533-437F7B71-0355-4272-974C-5D667C51E6FCQ38691946-B040DBB3-1454-443A-BE73-3168C14342FFQ38884741-BD44AC1C-5476-4AD0-8E15-01C3C46DE753Q39312420-49E7081C-EA22-4B14-AC5C-7662A98AA24AQ39598112-FAD44FDC-5410-4EEE-AAAF-F40F151F7725Q39639152-AFD0203F-662D-4997-85B1-B8B68D5018FE
P2860
Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Diagnostic dilemma of pseudopr ...... e promoter methylation status.
@en
Diagnostic dilemma of pseudopr ...... e promoter methylation status.
@nl
type
label
Diagnostic dilemma of pseudopr ...... e promoter methylation status.
@en
Diagnostic dilemma of pseudopr ...... e promoter methylation status.
@nl
prefLabel
Diagnostic dilemma of pseudopr ...... e promoter methylation status.
@en
Diagnostic dilemma of pseudopr ...... e promoter methylation status.
@nl
P2093
P2860
P356
P1476
Diagnostic dilemma of pseudopr ...... e promoter methylation status.
@en
P2093
P2860
P304
P356
10.3174/AJNR.A2286
P577
2011-01-20T00:00:00Z